Small molecule · Agonist of CD11b (ITGAM) · developed by GB006, Inc., a wholly owned subsidiary of Gossamer Bio
GB1275 is an orally bioavailable small molecule agonist of CD11b (ITGAM) that activates CD11b-mediated signaling to promote pro-inflammatory macrophage polarization and suppress immunosuppressive macrophage polarization. It reduces tumor-associated macrophages and myeloid-derived suppressor cells in the tumor microenvironment, promoting anti-tumor immune responses. It is studied in multiple solid tumors including pancreatic, esophageal, gastric, breast, prostate, colorectal, lung, head and neck, urothelial, renal, and hepatocellular cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04060342 | Phase 1 | Pancreatic Adenocarcinoma | Terminated | GOSS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-resistant Prostate CancerEsophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaMicrosatellite Stable Colorectal CancerNon-small Cell Lung CancerPancreatic AdenocarcinomaRenal Cell CarcinomaSmall-cell Lung CancerTriple Negative Breast CancerUrothelial Carcinoma
See GOSS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GOSS catalysts and pipeline →